Bioceltix S.A. Logo

Bioceltix S.A.

ISIN: PLBCLTX00019 | Ticker: BCX | LEI: 259400QZD5JYK8SLZU51

About Bioceltix S.A.

Company Description

Bioceltix is a team of experts working on innovative therapies for veterinary use. We work on biopharmaceuticals that harness the immunomodulatory properties of mesenchymal stem cells. We develop them following the highest quality and safety standards. We possess cutting-edge research and production facilities, cooperate with ambitious scientists, and operate under a well-developed business model. Our goal is to market new, effective solutions in the field of veterinary medicine.

The safety and efficacy of Bioceltix products will also be verified through field clinical trials carried out in accordance with Good Clinical Practice (GCP). The independent trials will be conducted in leading veterinary centres, under the supervision of the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL).

Year founded

2018

Served area

Worldwide

Headquarters

Bierutowska 57-59/Bud.Iii, 51-317 WrocΕ‚aw – Poland

Filings & Publications

Shareholder information

Shares outstanding

3,579,468

IPO

Nov. 1, 2021

Stock exchange(s)

Warsaw Stock Exchange

Contact Investor Relations department

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.